 |
|
|
| |
Ledipasvir / Sofosbuvir plus Ribavirin as highly effective regimen for RF1_2k/1b patients within Georgian national hepatitis C elimination program
|
| |
| |
Reported by Jules Levin
AASLD Liver Meeting Oct 20-24 2017, Washington DC
Marine Karchava, Nikoloz Chkhartishvili, Lali Sharvadze, Akaki Abutidze, Natia Dvali, Lana Gatserelia, Lela Dzigua, Natalia Bolokadze, Adam Kotorashvili, Paata Imnadze, Amiran Gamkrelidze, Muazzam Nasrullah, Juliette Morgan, Francisco Averhoff , Tengiz Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia, Hepatology Clinic Hepa, Tbilisi, Georgia, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia, National Center for Diseases Control and Public Health, Tbilisi, Georgia, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
|
| |
|
|
|
|
|
